Taken together, our results for doxorubicin treatment on primary cell lines in vitro and tumor-bearing mice in vivo suggest that Rac1b function is crucial for the doxorubicin-resistance of BCSC populations in Neu-driven tumors. Here, ERBB2 is linked to neoplasm.